SIGNAL TRANSDUCTION INHIBITORS AS NOVEL ANTICANCER DRUGS - WHERE ARE WE

被引：11
|
作者：
WORKMAN, P
机构：
[1] Cancer Research Campaign Beatson Laboratories, CRC Department of Medical Oncology, University of Glasgow, Scotland
来源：
ANNALS OF ONCOLOGY | 1992年 / 3卷 / 07期
关键词：
D O I：
10.1093/oxfordjournals.annonc.a058253
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：527 / 531
页数：5
相关论文
共 50 条
  • [41] Peptidomimetics and metalloprotease inhibitors as anticancer drugs
    SU Li & XU WenFang School of Pharmaceutical Sciences
    Science China Chemistry, 2009, 52 (05) : 535 - 548
  • [42] Novel Nrf2 inhibitors and their application to overcome chemoresistance of anticancer drugs
    Kumar, Vineet
    Foygel, Kira
    Paulmurugan, Ramasamy
    Malhotra, Sanjay V.
    CANCER RESEARCH, 2016, 76
  • [43] A-Review on Anticancer Agents: Conventional Drugs and Novel Target Specific Inhibitors
    Patel, Shivkant
    Sadhu, Piyushkumar
    Kumari, Mamta
    Dash, Dillip Kumar
    Jain, Surabhi
    Sen, Ashim Kumar
    ORIENTAL JOURNAL OF CHEMISTRY, 2023, 39 (03) : 657 - 669
  • [44] Discovery of novel AXL and MER inhibitors as potential anticancer and immune modulator drugs
    Hsieh, H-P.
    Li, M-C.
    Yen, W-C.
    Hsu, J. T-A.
    Yeh, T-K.
    Li, W-S.
    Wu, H-C.
    ANNALS OF ONCOLOGY, 2023, 34 : S214 - S214
  • [45] Signal transduction pathway targets for anticancer drug discovery
    Adjei, AA
    CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (04) : 361 - 378
  • [46] Alkylphospholipids are Signal Transduction Modulators with Potential for Anticancer Therapy
    Kaleagasioglu, Ferda
    Zaharieva, Maya M.
    Konstantinov, Spiro M.
    Berger, Martin R.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (01) : 66 - 91
  • [47] Deuterated drugs: where are we now?
    Timmins, Graham S.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2014, 24 (10) : 1067 - 1075
  • [48] Perspectives on the design and discovery of α-ketoamide inhibitors for the treatment of novel coronavirus: where do we stand and where do we go?
    Nocentini, Alessio
    Capasso, Clemente
    Supuran, Claudiu T.
    EXPERT OPINION ON DRUG DISCOVERY, 2022, 17 (06) : 547 - 557
  • [49] Angiogenesis inhibitors in clinical development; where are we now and where are we going?
    Eskens, FALM
    BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 1 - 7
  • [50] Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to
    Carofiglio, Francesca
    Trisciuzzi, Daniela
    Gambacorta, Nicola
    Leonetti, Francesco
    Stefanachi, Angela
    Nicolotti, Orazio
    MOLECULES, 2020, 25 (18):
12345